Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France

NCT ID: NCT03334019

Last Updated: 2018-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

559 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-06

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diseases naturally transmitted between animals and humans (zoonoses) are one of the leading causes of emergence or re-emergence of human infectious diseases. Non-foodborne zoonoses are commonly transmitted to human directly by contact with infected animals or contaminated environment. People working with animals such as farmers and veterinarians are particularly at risk of infection. Some zoonoses can also be transmitted indirectly thought the air and therefore can affect the general population. Example is Q fever, a disease caused by Coxiella burnetii, a bacterium highly resistant in the environment.

In Western France, Q fever is endemic in cattle herds. To improve human zoonotic disease surveillance, the investigators will conduct a population based study in this area.

The aims of the study are:

1. To assess seroprevalence of Coxiella burnetii infection among general population, farmers and veterinarians in Western France
2. To identify risk factors for Coxiella burnetii seropositivity in these populations

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In order to estimate seroprevalence and risk factors for Coxiella burnetii infection in humans, the investigators will conduct a cross-sectional study in three groups:

* blood donors at blood donation organizations (general population)
* beef and dairy cattle farmers
* veterinarians involved in a rural practice

All the participants in the study will provide a blood sample and will fill in a questionnaire.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Q Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

subjects

Data collected on general population, farmers and veterinarians though questionnaires and blood samples.

blood test

Intervention Type OTHER

Data collected on general population, farmers and veterinarians though questionnaires and blood samples.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood test

Data collected on general population, farmers and veterinarians though questionnaires and blood samples.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Give a written informed consent
* Be 18 years old and over
* Be able to speak French

Exclusion Criteria

* Adults under protection (guardianship or curators)
* Contraindication for drawing blood
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ONIRIS

INDUSTRY

Sponsor Role collaborator

Nantes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Leila Moret, PU-PH

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Nantes

Nantes, , France

Site Status RECRUITING

CHU de Nantes

Nantes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Leila Moret, PU-PH

Role: CONTACT

02.40.84.69.24

Marie Pouquet, PharmD

Role: CONTACT

02.40.68.78.21

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Leila Moret Moret, PU-PH

Role: primary

02.40.84.69.24 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC16_0420

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.